Immunizations

Rite Aid announced that at select Rite Aid locations, including Rite Aid-owned Bartell Drugs, it will be providing Pfizer-BioNTech COVID-19 vaccines to children ages 3 years old and older once shipments arrive to select pharmacies later this week.

Priorix (measles, mumps and rubella vaccine, live) is indicated for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months old and older.

The Biden administration is planning for all scenarios, including for the first vaccinations to start as early as the week of June 20, with the program ramping up over time.

​​​​​​​If emergency use authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine available in the United States.

Sixty-six percent of pharmacists would be prepared to administer COVID-19 vaccines to children under 5 years old if authorized to do so.

The FDA has authorized a single booster dose for individuals aged 5 to 11 years old at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 vaccine.

Moderna's submission to the FDA is based on Phase 2/3 studies of mRNA-1273 in young children.

The Austin Public Health department of Austin, Texas has become the nation’s first health department recipient of the firm’s Exemplary Provider Certification program for Immunization and Testing Services.

This allocation effort is a part of the Federal Retail Pharmacy Program for COVID-19 Vaccination, which includes Good Neighbor Pharmacy.

The FDA authorized a second booster dose in adults aged 50 years old and older and for those aged 12 years old and older with compromised immune systems.

Moderna said that it will submit a request for authorization of a 25 μg two-dose primary series of mRNA-1273 for children aged 6 months old to under 6 years old to the FDA, EMA and other global regulators in the coming weeks.

Thirty-five generic manufacturers have signed agreements with the MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for 95 low- and middle-income countries.